Search Results

Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard) announces today that it has selected its lead candidate for MDG2021, a T cell receptor engineered T cell (TCR-T) therapy targeting Kirsten rat sarcoma viral oncogene homologue (KRAS) G12D with human leukocyte antigen (HLA)-A*11 being developed in combination with the Company’s PD1-41BB costimulatory switch protein (CSP) technology.

Medigene AG, an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, reported financial results for the first quarter of 2024.

Medigene AG, an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announced the submission of three patents to the European Patent Office.

Medigene AG announced that the Company has been issued a patent by the European Patent Office protecting its inducible Medigene T cell receptor technology, which contains a control mechanism to regulate efficacy and improve safety of its T cell receptor engineered T cell therapies.

Medigene AG reported financial results for the fiscal year ended December 31, 2023, and provided a corporate update.

Medigene AG, an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announces the results of the Annul General Meeting.

Medigene AG will report financial results and provide a corporate update for the fiscal year ended December 31, 2023, on Thursday, March 28, 2024.

Medigene AG will be participating in the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference on March 26, 2024.

Medigene AG will present virtually at the 7th Cell and Gene Therapy In-Depth Focus Summit taking place from June 27-28, 2024, in Beijing, China.